DIRS.INFO The most relevant business & tech news

☆ Kelly Osbourne defends using Ozempic for weight loss: 'I think it's amazing'
▼ + stars: | 2024-02-16 | by ( Olivia Singh | ) www.businessinsider.com time to read: +2 min

Read previewKelly Osbourne shared in a recently published interview that she's fully in support of using Ozempic, days after her mother, Sharon Osbourne, made headlines criticizing the drug for its effects. "I think it's amazing," Osbourne told E! Stars like Amy Schumer and Chelsea Handler have been outspoken about their negative experiences using Ozempic. Sharon previously cautioned against using Ozempic and said losing weight can become addicting. News, Kelly explained why she thinks the weight-loss drug is spoken about in a negative light.

Persons: —, Kelly Osbourne, she's, Sharon Osbourne, Osbourne, who's, Jae C, Amy Schumer, Chelsea Handler, Sharon, Kelly Organizations: Service, CBS, Business, Guardian, BI

☆ How to access the new weight loss drugs
▼ + stars: | 2024-02-15 | by ( Andrea Kane | ) edition.cnn.com time to read: +7 min

(CNN) — By now, it is pretty clear that the new weight loss and diabetes medications have achieved blockbuster status. Unlike previous weight loss medications, they are pretty effective at helping people lose weight and keep it off — between around 15% to 20% of body weight — with relatively few side effects (although some people can’t tolerate them, and a fraction of patients experience more severe side effects). Zepbound, the newly approved weight loss drug from Eli Lilly, may be easier to find. “Otherwise, some physicians are prescribing older, generic weight loss medications that can be helpful for some patients.”These drugs are not right for everyoneFor many people, the cultural pressure to look a certain way is high. And join us next week on the Chasing Life podcast when we talk to WeightWatchers CEO Sima Sistani about whether these new weight loss drugs really signal the end of diet culture.

Persons: Sanjay Gupta ”, Eli Lilly, Goldman Sachs, Meg Tirrell John Nowak “, Meg Tirrell, Sanjay Gupta, ” Tirrell, “, ” Eli Lilly, Tirrell, ”, Sima Sistani Organizations: CNN, —, Trilliant Health, Novo Nordisk, US Food and Drug Administration, “, Nordisk, ”

☆ Sharon Osbourne swears off weight loss and cosmetic treatments after experiencing the downsides of Ozempic
▼ + stars: | 2024-02-11 | by ( Eve Crosbie | ) www.businessinsider.com time to read: +3 min

Read previewSharon Osbourne has expressed regret over taking the buzzy weight-loss drug Ozempic, stating that she now weighs less than 100 pounds and "can't put on weight." In an interview with The Guardian, Osbourne, 71, highlighted the downsides of Ozempic, a diabetes drug that also causes weight loss. She said that after dropping 42 pounds in four months, she's now "through with the weight loss and all that cosmetic stuff." Osbourne has previously talked about her experience taking the weight loss drug. Sharon Osbourne said her husband Ozzy Osbourne claims she looks like Nancy Reagan following her weight loss.

Persons: —, Sharon Osbourne, Osbourne, she's, Ozzy Osbourne, Nancy Reagan, Gregg DeGuire, I've, it's, Ozempic, Elon Musk, Charles Barkley, Amy Schumer Organizations: Service, Guardian, Business, Daily Mail, The Recording, Ozempic, FDA, The Times

☆ Ro, the $7 billion healthcare startup, has a high-stakes strategy to take off-brand Ozempic mainstream
▼ + stars: | 2024-02-07 | by ( ) www.businessinsider.com time to read: +11 min

The $7 billion healthcare startup Ro, which has been prescribing brand-name weight-loss shots since January 2023, now offers compounded semaglutide to patients enrolled in its weight-management program. Nonetheless, Ro is the first prominent healthcare company to effectively endorse compounded semaglutide by prescribing it. A poor-quality compounded drug might simply be a dud and a waste of money. But while compounding pharmacies are subject to FDA and state regulations, states are the main regulators, and their oversight is patchy. Michael Siluk/UCG/Universal Images Group via Getty ImagesIt's hard to know if any given vial of compounded semaglutide is safe.

Persons: Wegovy's, Ro, drugmakers, Eli Lilly's, Eli Lilly's Mounjaro, Scott Gottlieb, Michael Siluk, That's, they've, Ozempic, Eli Lilly, Eric Kastango, they're, Kastango, aren't, Al Carter, Sarah Jones Simmer, Spencer Nadolsky, WeightWatchers, Tim Church, Wondr, it's, hasn't Organizations: Business, Novo Nordisk's Wegovy, US Food and Drug Administration, FDA, Novo Nordisk's Ozempic, Getty, Novo Nordisk, USP, National Association of, Pharmacy, Health Locations: Novo, Massachusetts, Austria, New York City

☆ Eli Lilly says weight loss drug shows promise as treatment for fatty liver disease
▼ + stars: | 2024-02-06 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Eli Lilly on Tuesday said its highly popular drug used for weight loss and diabetes showed promise as a treatment for fatty liver disease in a mid-stage trial. The condition is characterized by excess fat build-up and inflammation in the liver and can lead to liver scarring, also known as fibrosis. The trial followed around 190 adults with MASH with severe stages of liver scarring, Eli Lilly executives said on an earnings call Tuesday. It was less clear how much the drug reduced liver scarring, which was the second aim of the trial. Eli Lilly is "equally encouraged" by tirzepatide's results in reducing liver scarring, the company's chief scientific officer Dan Skovronsky said on the call.

Persons: Eli Lilly’s, Eli Lilly, tirzepatide, Dan Skovronsky, David Risinger, Eli Lilly's Organizations: Leerink, Novo Nordisk Locations: New York City, U.S

☆ Tirzepatide: Weight loss drug helps significantly lower blood pressure in adults who are overweight or obese, study finds
▼ + stars: | 2024-02-05 | by ( Mira Cheng | ) edition.cnn.com time to read: +6 min

The participants had their blood pressure monitored for a day before beginning treatment and again after nine months of weekly tirzepatide injections. The results showed a significant decrease in the participants’ systolic blood pressure, the top number in blood pressure readings, which is a strong predictor of heart disease. It works similarly to semaglutide, the active compound in the weight loss drug Wegovy and its sister diabetes drug, Ozempic. Although there are effective blood pressure medications available, only about a quarter of people with hypertension have adequately controlled blood pressure, Hall said. He views the weight loss effect of the drug as a pleasant side effect that will make people more likely to take their medication.

Persons: —, Eli Lilly, ”, Harlan Krumholz, Michael E, Wegovy, it’s, Ania Jastreboff, Hall, Krumholz, tirzepatide, Dr, Sanjay Gupta, CNN’s Meg Tirrell Organizations: CNN, American Heart Association, Food and Drug Administration, Yale University, Department of Medicine, University of Mississippi Medical Center, Yale Obesity Research Center, CNN Health Locations: United States

☆ What to know about medications like Ozempic, Wegovy, Mounjaro and Zepbound for weight loss
▼ + stars: | 2024-02-03 | by ( Andrea Kane | ) edition.cnn.com time to read: +8 min

Editor’s note: Season 9 of the podcast Chasing Life With Dr. Sanjay Gupta explores the intersection between body weight and health. But anyone who has ever dieted can tell you that losing weight is hard and that long-term weight loss requires sustained effort, which can sometimes feel Herculean, even impossible. If you are considering starting one of these medications, Moreno recommends keeping these five facts in mind. “On average, with semaglutide, the weight loss average can be close to 15%. This is the time to start changing some eating patterns that will be beneficial for weight loss.

Persons: Sanjay Gupta, Ozempic, It’s, Jorge Moreno, Moreno, ‘ You’ve, ”, ” Moreno, “, Tirzepatide, Food and Drug Administration — “, They’re, ” They’re, —, “ It’s, GERD, ” It’s, ’ ” Moreno Organizations: CNN, Yale School of Medicine, LinkedIn, Food and Drug Administration

☆ Norway's giant wealth fund touts possibility of Novo Nordisk, Eli Lilly joining the trillion-dollar club
▼ + stars: | 2024-01-31 | by ( Sam Meredith | ) www.cnbc.com time to read: +1 min

A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. Norway's giant wealth fund, the world's largest, touted the possibility that Danish drugmaker Novo Nordisk and U.S. rival Eli Lilly could be on course to become the first healthcare members of the trillion-dollar club. Novo Nordisk, Europe's largest firm by market capitalization, on Wednesday reported stronger-than-anticipated 2023 earnings, as sales of its hugely popular drug Wegovy continued to soar. The largest pharmaceutical company in the world by market value, Eli Lilly currently stands at roughly $612 billion. NBIM, the world's biggest single stock market investor, holds a 2.5% stake in Novo Nordisk and a 0.98% stake in Eli Lilly, according to LSEG data.

Persons: Eli Lilly, Wegovy, Gemma Game, Eli Lilly's Zepbound Organizations: Novo Nordisk, Pharmacy, Norges Bank Investment Management, Nordisk's Ozempic Locations: Provo , Utah, U.S, Danish, Europe's

☆ 'Botched' star Terry Dubrow calls Ozempic 'a miracle' but admits it takes 'all the joy of eating away'
▼ + stars: | 2024-01-22 | by ( Amanda Goh | ) www.businessinsider.com time to read: +2 min

"Botched" star and plastic surgeon Terry Dubrow told Page Six that he tried Ozempic. Dubrow called the weight-loss drug "a miracle" but admitted it took "all the joy of eating away." He said he wanted to see what it's like if you're not diabetic and "only have 10-15 pounds to lose." Advertisement"Botched" star Terry Dubrow says he tried Ozempic but gave it up because it took "all the joy of eating away." In a Page Six interview alongside costar Paul Nassif, the plastic surgeon admitted to giving the weight-loss drug a go because he was curious about its effects.

Persons: Terry Dubrow, Dubrow, —, Paul Nassif, Evan Real, Heather Dubrow — Organizations: Service, Page, Housewives, FDA Locations: Orange

☆ A doctor lost 50 pounds and has kept it off for years after ditching fad diets. She eats high-protein food and does intermittent fasting.
▼ + stars: | 2024-01-18 | by ( Rachel Hosie | ) www.businessinsider.com time to read: +7 min

Research shows that there is nothing special about intermittent fasting for weight loss, and it doesn't work for everyone because it can be challenging to maintain. But it helps some people stick to a calorie deficit, which is required for weight loss. Protein is helpful for weight loss because it keeps you feeling full and helps the body maintain muscle during a calorie deficit. AdvertisementAfter a few months, her new lifestyle felt normal and she continued intermittent fasting after finishing her weight loss phase. Grunch believes weight loss is about mindsetGrunch is now aiming to maintain her weight and will see how that goes without medication.

Persons: Betsy Grunch, Grunch, —, Carbs, I've Organizations: Service, aha, Research Locations: Atlanta , Georgia

☆ What weight tells us about our health
▼ + stars: | 2024-01-17 | by ( Dr. Sanjay Gupta | ) edition.cnn.com time to read: +12 min

(CNN) — If you’ve been paying attention to health news recently, you may have noticed a subtle but real shift in the way society discusses body weight. Beyond health care dollarsDespite changing attitudes about larger bodies, excess weight does carry a price. From a health care standpoint, it costs the country a lot of money. According to a study published in the journal The Lancet in 2020, 27% of total health care expenditures in 2016 — about $730.4 billion — could be attributed to “modifiable risk factors” for preventable health conditions like cardiovascular disease. That was eight years ago, when our total health care expenditure was $2.7 trillion, according to the study.

Persons: you’ve, We’re, Dr, Fatima Cody Stanford, “, They’re, Adolphe Quetelet, Ancel Keys, ”, ” Stanford, Morgan, That’s, we’ll, Daniel Lieberman, who’ll, Oprah Organizations: CNN, American Medical Association, Massachusetts General Hospital, Harvard Medical School, National, bloodwork, Harvard Locations: Belgian

☆ Questions and answers for weight loss medications semaglutide and tirzepatide
▼ + stars: | 2024-01-17 | by ( Katia Hetter | ) edition.cnn.com time to read: +10 min

CNN —As prescriptions for popular weight loss drugs have soared, the class of medications known as GLP-1 agonists is changing the way people think about how to lose weight. Initially developed to treat type 2 diabetes, medications like semaglutide and tirzepatide have also been shown to be effective in promoting weight loss. Also, some people would do well without medications and could have sufficient weight loss with changes in diet and exercise. Wen: The FDA-approved versions of semaglutide and tirzepatide for weight loss are called Wegovy and Zepbound. CNN: Are there certain medications that preclude you from taking the weight loss drugs at the same time?

Persons: Leana Wen, Wen, Michael Siluk, tirzepatide, It’s, Eli Lilly Organizations: CNN, US Food and Drug Administration, George Washington University, FDA, BMI, Getty Images CNN, The New England, of Medicine, Novo Nordisk, semaglutide Locations: The

☆ Opinion: What Oprah gets right about diet culture
▼ + stars: | 2024-01-11 | by ( Opinion Adrienne Bitar | ) edition.cnn.com time to read: +6 min

How could she, the queen of WeightWatchers and doyenne of dieting, be abandoning the equation of diet + exercise = slim? Taking weight-loss drugs, rejecting diet culture or choosing to diet are all valid health decisions. Just look at the tragic history of diet drugs. When considered in this context, semaglutide isn’t the weight loss panacea it may appear to be. Oprah and the millions of other Americans on prescription semaglutide and similar medications should be respected — or at least not ridiculed — for ignoring the insults and choosing what’s right for them, drug or no drug, diet or no diet.

Persons: Adrienne Bitar, ”, Oprah Winfrey, WeightWatchers, Oprah, couldn’t, Cancer, dieters, “, gaunt, Jimmy Kimmel, Atkins “, John Harvey Kellogg, Kellogg, dieter, — Organizations: “, Studies, Cornell University, CNN, ”, Federal Food

☆ Oprah's flip on weight loss drugs is a sign of what's to come for the 'Ozempic trade' in 2024
▼ + stars: | 2023-12-25 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +10 min

Lilly's Zepbound recently entered the weight loss market, and is off to a strong start. But what's ahead for the weight loss trade in 2024? Beyond weight loss One of 2023's most pivotal events in the space was Novo Nordisk's release of top line results from its Select trial in August . In 2023, the exuberance around weight loss drugs roiled markets in many unexpected ways. The affected companies have also been very vocal in addressing how they plan to coexist with these weight loss products.

Persons: Oprah Winfrey, Eli Lilly, they've, Lilly's, Lilly's Zepbound, Andy Acker, Janus Henderson's, Lilly, Novo, FactSet, Acker, Janus, Buzz, Gregory Renza, Renza, Goldman Sachs, Chris Shibutani, Mike Kratky, Kratky, Dexcom, Leerink, Winfrey, I've, Winfrey's, Michael Bloom Organizations: Novo Nordisk, Wall Street, Wall, RBC Capital, Pfizer, Structure Therapeutics, AstraZeneca, Leerink, Nestle, Oprah Daily, Winfrey, International Locations: Friday's, Eccogene, MedTech, 3Q23

☆ Healthcare companies are promising to help patients quit Wegovy. There's just one problem with that.
▼ + stars: | 2023-12-19 | by ( ) www.businessinsider.com time to read: +11 min

Inkinen said Virta can help patients quit GLP-1 drugs and keep weight off by adjusting the foods they eat to help them feel full, similar to how the drugs reduce feelings of hunger. About 82% of patients taking Wegovy experience gastrointestinal issues like nausea and diarrhea. WeightWatchers didn't provide Business Insider with published data to support its claims that it can help people keep weight off after quitting weight-loss drugs. AdvertisementHe also advises the weight-loss startup Calibrate, which tapers some patients off GLP-1 drugs after they reach a certain body-mass index. GLP-1 drugs also slash the risk of heart attacks, strokes, and cardiac-related death.

Persons: —, Michael Albert, aren't, Sami Inkinen, Inkinen, Virta, Michael Siluk, Noom's, Linda Anegawa, Carolina Rudah, tirzepatide, Mounjaro, Zepbound —, Eli Lilly, Ozempic, Wegovy, Randy Seeley, Seeley, Robyn Phelps, it's, Robert Kushner, Kushner, Florian Gaertner, It's, Albert, Lisa, she's, I'm Organizations: Service, Business, FDA, Virta, Getty, Nordisk, Michigan Nutrition Obesity Research, University of Michigan, Novo Nordisk, Northwestern University Locations: Denver, Michigan

☆ Why Pfizer's latest stumble in the obesity market is a boon for Eli Lilly
▼ + stars: | 2023-12-01 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +5 min

In June, the New York-based pharmaceutical giant stopped developing a different obesity pill, known as lotiglipron , due to concerns about liver safety. Meanwhile, Eli Lilly shares were mainly flat in afternoon trading, at around $591apiece. We lifted our Eli Lilly price target Friday to $630 per share, up from $600. Eli Lilly and Danish rival Novo Nordisk (NVO) are the two dominant players in the obesity market. The longer it takes for competitors to get to this burgeoning market, the more revenue first-movers Eli Lilly and Novo Nordisk can capture.

Persons: Eli Lilly, Jim Cramer, Lilly's, Novo's, Jim, Eli Lilly —, —, Eli, that's, — Novo's, Novo, semaglutide, Jim Cramer's, AJ Mast Organizations: Pfizer, Club, Novo Nordisk, Pharmaceutical, Amgen, AstraZeneca, Bank of America, U.S . National Library of Medicine, U.S . Food, Drug Administration, CNBC, Bloomberg, Getty Locations: New York, Danish, Lilly, U.S, Indianapolis , Indiana

☆ US obesity docs expect Lilly weight-loss drug to show similar heart benefit as Wegovy
▼ + stars: | 2023-12-01 | by ( Patrick Wingrove | ) www.reuters.com time to read: +5 min

REUTERS/Mike Segar Acquire Licensing RightsDec 1 (Reuters) - Some leading U.S. obesity specialists say they expect Eli Lilly’s (LLY.N) powerful weight-loss drug Zepbound will produce the same or similar heart benefits as Novo Nordisk’s (NOVOb.CO) popular Wegovy as they belong to the same class of medicines. In Novo's pivotal Wegovy trial involving 17,604 overweight and obese people without diabetes, the drug reduced incidence of heart attack, stroke or heart-related death by an impressive 20%. The product, which has the same active ingredient - tirzepatide - as its previously approved diabetes drug Mounjaro, is expected to start shipping it before the end of the year. They said they would readily prescribe Wegovy (semaglutide) if their patients' insurance did not cover Lilly’s drug, or if future trial results do not produce similar heart benefits. Lilly declined to comment on doctors' views that Zepbound might have the same or similar cardiovascular benefits as Wegovy.

Persons: Eli Lilly, Mike Segar, Eli Lilly’s, Lilly, Danish drugmaker, Edmond Wickham, Emily, Zepbound, Tirzepatide, ”, Rohit Kedia, Novo, Chad Weldy, semaglutide, tirzepatide, Farxiga, Boehringer Ingelheim, Lilly’s Jardiance, Patrick Wingrove, Caroline Humer, Bill Berkrot Organizations: Company, REUTERS, Novo, Wegovy, Virginia Commonwealth University . The, Virginia Commonwealth University . The U.S . Food, Drug Administration, Wall Street, Barclays, Providence, Stanford University, Thomson Locations: Branchburg , New Jersey, Danish, Virginia Commonwealth University . The U.S, Zepbound, U.S

☆ Novo Nordisk finds compounded Wegovy up to 33% impure, sues Florida pharmacies
▼ + stars: | 2023-11-30 | by ( Patrick Wingrove | ) www.reuters.com time to read: +3 min

[1/2] Injection pens of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, November 21, 2023. The Danish drugmaker said it found impurities in all the drugs tested from Wells Pharmacy and Brooksville Pharmaceuticals, both based in Florida. Novo said the compounded versions of Wegovy tested from Brooksville were also less potent than advertised, with one sample shown to be at least 19% weaker than indicated. The drugmaker has already filed 12 lawsuits against medical spas, weight-loss clinics and compounding pharmacies offering products that claim to contain semaglutide. The case against Wells was filed in the U.S. District Court, Middle District of Florida, Ocala division and the suit against Brooksville in U.S. District Court, Middle District of Florida, Tampa division.

Persons: Victoria Klesty, Danish drugmaker, Novo, Brooksville, ” Jason Brett, Eli Lilly, Mounjaro, Wells, Patrick Wingrove, Josephine Mason, Bill Berkrot, Jane Merriman Organizations: REUTERS, Novo Nordisk, Wells Pharmacy, Brooksville Pharmaceuticals, U.S . Food, Drug Administration, FDA, Novo's, Middle District of, Brooksville, Thomson Locations: Oslo, Norway, Victoria, Danish, Florida, Wells, U.S, Middle District, Middle District of Florida, Ocala, Tampa

☆ Novo Nordisk sues two pharmacies for allegedly selling tainted Wegovy, Ozempic knockoffs
▼ + stars: | 2023-11-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Compounding pharmacies prepare custom-made versions of commercially available treatments to meet the specific needs of a patient. Novo Nordisk first sued Brooksville Pharmaceuticals over copycat versions of Wegovy and Ozempic in July. Including the newest lawsuits, Novo Nordisk has filed 12 legal actions against compounding pharmacies, medical spas and weight loss clinics allegedly selling dupes of Wegovy and Ozempic. That puts patients "at risk of taking drug products that are less effective than expected based on their labeling," according to Novo Nordisk. Several states have also threatened to take legal action against compounding pharmacies that make or distribute unapproved variations of Novo Nordisk's weight loss treatments.

Persons: Eli Lilly, Jason Brett, Novo Organizations: Novo Nordisk, Wells Pharmacy Network, Brooksville Pharmaceuticals, Nordisk, Wells Pharmacy, Novo, U.S . Food, Drug Administration, FDA, CNBC PRO Locations: Oslo, Norway, Florida, U.S, Danish, Ozempic

☆ Sima Sistani says its time for WeightWatchers to embrace Ozempic. Will its users agree?
▼ + stars: | 2023-11-28 | by ( Nicole Goodkind | ) edition.cnn.com time to read: +10 min

Sima Sistani, the 44-year-old CEO of WeightWatchers, is aware of this, and she recognized WeightWatchers had to evolve – or else. She also landed a massive deal to buy a telehealth business that can issue virtual prescriptions to patients for these weight loss drugs. Semaglutide was approved by the US Food and Drug Administration to treat type 2 diabetes as Ozempic, but it was also used off-label for weight loss. Some longtime users of the program feel betrayed by the pivot away from in-person meetings and toward medication-based solutions. “Sadly, they don’t want to do the work,” she said, of tracking food or exercising to achieve weight loss goals.

Persons: New York CNN —, Sima Sistani, WeightWatchers, she’s, Sistani, “, ” Sistani, Erica Shroeder, ”, Jaap Arriens, ” Goldman Sachs, Jenny Craig, Adam Rockmore, Ged, Angela Weiss, Variety Sistani, there’s, Semaglutide, aren’t, “ there’s, Oprah Winfrey, Jamie Yonash, influencers, Velanti, Michael Nagle, We’re Organizations: New, New York CNN, Walmart, CNN, WeightWatchers, Variety, US Food and Drug Administration, Bloomberg, Getty Locations: New York, Cola, Wegovy

☆ Suspected fake Ozempic causes hypoglycemia in 11 in Lebanon
▼ + stars: | 2023-11-28 | by ( Patrick Wingrove | ) www.reuters.com time to read: +4 min

Three of the people who took the suspected fake Ozempic did so to control their diabetes, while four took it for weight management, Karam said. People with diabetes need to closely manage their blood sugar, which can be done with a variety of medicines including Ozempic. Lebanon's Ministry of Public Health issued two recalls related to Ozempic in January 2023, according to its website. Karam said Ozempic is neither purchased nor provided by the Ministry of Public Health. Several people have been hospitalized in Austria for hypoglycemia after taking potentially fake versions of Ozempic.

Persons: Rita Karam, Eli Lilly's, Novo's, Karam, Ozempic, Patrick Wingrove, Caroline Humer, Bill Berkrot Organizations: Lebanese Ministry of Public Health, Lebanon's Ministry of Public Health, Novo Nordisk, World Obesity, Obesity, International Diabetes Federation, Ministry of Public Health, Reuters, Thomson Locations: Lebanon, Germany, Egypt, Russia, United States, Novo, Britain, Belgium, Austria

REUTERS/George Fre/File Photo Acquire Licensing RightsNov 27 (Reuters) - Overweight or obese adults lost more weight and shed pounds faster using Eli Lilly's (LLY.N) Mounjaro than those taking Novo Nordisk's (NOVOb.CO) popular rival weight loss drug, according to an analysis of health records and other data. After 3 months of treatment, patients on Mounjaro had lost an average of 2.3% more body weight than those taking Ozempic, the study also found. By 6 months, the difference had widened to 4.3%, and by 12 months, the Mounjaro group had lost an average of 7.2% more weight. An Eli Lilly spokesperson said the company does not promote or encourage the off-label use of any of its medicines, although its drug is now approved for weight loss. A trial is underway comparing the weight loss formulations of the two injected medicines in patients overweight or obese but without type 2 diabetes.

Persons: Lilly, George Fre, Eli Lilly's, Mounjaro, Eli Lilly, Nancy Lapid, Bill Berkrot Organizations: Novo Nordisk, Pharmacy, REUTERS, Novo, Thomson Locations: Provo , Utah, U.S

☆ Ozempic maker plans manufacturing blitz as market for the drug is expected to top $100 billion in 2030
▼ + stars: | 2023-11-23 | by ( Jake Swearingen | ) www.businessinsider.com time to read: +2 min

Novo Nordisk makes Ozempic and Wegovy, two hit drugs that treat obesity. In the past two weeks, it's announced more than $8 billion in manufacturing investments. AdvertisementNovo Nordisk, maker of the popular anti-obesity drugs Ozempic and Wegovy, is investing billions to ramp up production capacity amid surging demand. The move comes just after Novo Nordisk unveiled plans to shell out over $6 billion to expand manufacturing capacity in Denmark. That money will go toward increasing production capacity for semaglutide, the key ingredient in Ozempic and related medications.

Persons: it's, —, Ozempic, Emmanuel Macron, Eli Lilly, David Ricks, Lilly, Goldman Sachs Organizations: Novo Nordisk, Service Locations: France, Chartres, Denmark, Europe, Novo

Injection pens and boxes of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, November 21, 2023. REUTERS/Victoria Klesty/Illustration Acquire Licensing RightsSummaryCompanies Novo racing to meet demand for obesity drugsObesity market to reach $100 billion by 2030-analystsNew investment in France will boost capacity for obesity, diabetes drugsPARIS/LONDON Nov 23 (Reuters) - Novo Nordisk (NOVOb.CO) on Thursday announced a $2.3 billion investment to boost production of its wildly popular weight-loss and diabetes drugs at a site in Chartres, France as it races to meet soaring demand. There is a growing crisis in Europe over supply of diabetes therapy Ozempic, which uses the same ingredient semaglutide as the hugely popular weight-loss drug Wegovy, which is not yet widely available in Europe. Thursday's announcement comes after Novo earlier this month announced a $6 billion investment in its native Denmark to boost production. Analysts have estimated the obesity drug market will be worth as much as $100 billion by 2030.

Persons: Victoria Klesty, Danish drugmaker, Emmanuel Macron, Lars Fruergaard Jorgensen, Eli Lilly, Novo, Anna Ringstrom, Ludwig Burger, Terje Solsvik, David Goodman, Emelia Organizations: REUTERS, Novo Nordisk, WIN, French, Thomson Locations: Oslo, Norway, Victoria, France, PARIS, Chartres, Danish, Europe, Union, Germany, Belgium, Denmark, U.S, Paris

Handout via REUTERS/File photo Acquire Licensing RightsSummaryCompanies Ozempic shortages expected throughout 2024Victoza shortages expected until at least Q2 2024Diabetes drug Ozempic used 'off label' to treat obesityNov 21 (Reuters) - Novo Nordisk (NOVOb.CO) will ration starter kits of Ozempic in Europe and reduce supplies of another diabetes drug, Victoza, to prioritise producing Ozempic, which has seen a surge in demand from people using it to lose weight. Ozempic contains semaglutide, an ingredient in Novo's hugely popular anti-obesity drug Wegovy. Intermittent Ozempic shortages are expected throughout 2024, while Victoza shortages are expected at least until the second quarter of 2024, according to the statement on the EMA's website. "No new patients should be started on Victoza until at least Q2 2024 when supply is expected to normalise," Novo urged doctors in the document. It also told doctors to consider other injectable GLP-1 drugs or "other suitable alternatives" where Ozempic or Victoza are not available for patients.

Persons: Ozempic, hasn't, Novo, Eli Lilly's, tirzepatide, Ludwig Burger, Eva Mathews, Emelia Sithole, Mark Potter Organizations: Handout, REUTERS, Diabetes, Novo Nordisk, European Medicines Agency, EU, Thomson Locations: Novo, London, Britain, Europe, Danish, United States, France, Austria, Belgium, Germany, Wegovy, Norway, Denmark, EU

Search resuls for: "Semaglutide"

25 mentions found